Daiichi Sankyo, AstraZeneca team with Summit to test Datroway-ivonescimab combo in cancer trials

• Daiichi Sankyo entered a clinical trial collaboration with AstraZeneca, Summit Therapeutics to test Datroway with ivonescimab across solid tumors.
• Program starts with a phase 3 trial in first-line triple-negative breast cancer, targeting expansion into other settings including lung cancer.
• AstraZeneca or Daiichi Sankyo will sponsor the studies; all three companies will share trial costs.
• Each partner keeps development and commercial rights to its own drug in the combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.